Product Description
Cinepazide is an olefinic compound. It derives from a cinnamic acid.Cinepazide has been used in trials studying the treatment of Ischemic Stroke. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Cinepazide)
Mechanisms of Action: Calcium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Korea
Approved Indications: None
Known Adverse Events: None
Company: Qilu
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Ischemic Stroke
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20231896 | N/A |
Completed |
Ischemic Stroke |
2023-07-26 |
|
ChiCTR1900023827 | N/A |
Not yet recruiting |
Ischemic Stroke |
2019-06-30 |
|
CTR20160292 | P4 |
Completed |
Ischemic Stroke |
2019-02-01 |
|
CTR20160417 | P4 |
Completed |
Ischemic Stroke |
2018-05-31 |